Cost Per Patient of Treatment for Rifampicin-Resistant Tuberculosis in a Community-Based Programme in Khayelitsha, South Africa

The high cost of rifampicin-resistant tuberculosis (RR-TB) treatment hinders treatment access. South Africa has a high RR-TB burden, and national policy outlines decentralisation to improve access and reduce costs. We analysed health system costs associated with RR-TB treatment by drug resistance profile and treatment outcome in a decentralised programme.